SSX family member 2Genealiases: CT5.2 · CT5.2A · HD21 · HOM-MEL-40 · SSX
Q-omics provides the consensus-scored SSX2 profile across patient tissues and cancer cell-line models. SSX2 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SSX2 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, SSX2 RNA expression shows 8,447 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BRCA, and THYM as cancer lineages where SSX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSX2 survival associations across molecular data types. SSX2 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSX2 RNA expression–survival associations across cancer types. High SSX2 expression shows unfavorable associations in KIRC, HNSC, UCEC, LIHC, LUAD and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SSX2 RNA expression.
This table summarizes SSX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SSX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSX2 shows higher tumor expression in BRCA, LIHC and PRAD. The BRCA box plot shows higher SSX2 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .029).
This table shows molecular features associated with SSX2 in patient tissues and cancer cell lines. In patient samples, SSX2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SSX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
